UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires Shares of 55,696 Astria Therapeutics, Inc. (NASDAQ:ATXS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 55,696 shares of the biotechnology company's stock, valued at approximately $613,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.10% of Astria Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of ATXS. Bank of New York Mellon Corp grew its stake in shares of Astria Therapeutics by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company's stock valued at $1,266,000 after acquiring an additional 8,965 shares during the period. Panagora Asset Management Inc. increased its stake in shares of Astria Therapeutics by 104.7% in the second quarter. Panagora Asset Management Inc. now owns 30,926 shares of the biotechnology company's stock worth $281,000 after purchasing an additional 15,816 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Astria Therapeutics by 4.1% during the 2nd quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company's stock valued at $595,000 after buying an additional 2,556 shares in the last quarter. Quest Partners LLC boosted its holdings in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after buying an additional 3,112 shares during the period. Finally, ClariVest Asset Management LLC purchased a new stake in Astria Therapeutics in the 2nd quarter worth $731,000. Hedge funds and other institutional investors own 98.98% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ATXS. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, December 10th. Oppenheimer boosted their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $25.60.

Astria Therapeutics Stock Up 1.2 %

Shares of Astria Therapeutics stock opened at $9.56 on Friday. The firm has a market cap of $539.51 million, a price-to-earnings ratio of -4.57 and a beta of 0.67. Astria Therapeutics, Inc. has a twelve month low of $5.94 and a twelve month high of $16.90. The business has a 50-day moving average price of $10.70 and a 200-day moving average price of $10.69.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.